Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1409)	8/7/2000 3:23:56 PM
From: sim1	Read Replies (2) \| Respond to of 52153

How about QTRN, MCDE, or NTII? SKYE seems to be permanently stuck. It's been almost a year since the BPUR So. African fast track announcement. Shouldn't we be hearing something from them soon? Also, does BLUD count?

To: Biomaven who wrote (1409)	8/7/2000 4:15:43 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 52153

Peter, Regarding Biogen... I sold my holdings a few months ago at a rediculously overvalued price. I did so because: 1. The two most exciting compounds (to me) in the clinic - VLA4 and Antova - both were yanked from trials. 2. CVT124 launch seems to have fallen back a couple of years to a possible 2004/5 launch. 3. Amevive looks great, buy psoraiasis market is tough and there are lots of treatments in pipelines all over biopharm. Plus, am unsure what to expect from sales curve: this is not a drug like Avonex that will be taken every week by loyal patients. 4. The company is not putting its money to use (so far) - no inlicensing, no company purchases. It was hinted recently that something might be imminent, but that has been hinted at for 3 years now. 5. Avonex is only the best of a poor lot of treatments for MS. Like psoraiasis, MS has lots of companies searching for a better treatment (including Biogen). 6. I recall the company saying during a conference call over a year ago, that Biogen would submit a new IND by the end of last year. It never materialized. The company has a good balance sheet, good physical plant and wonderful people. Hopefully, their sails will fill again, but now I think they are becalmed and I don't think the company is a value at 30X earnings, a slowing growth rate, a shrinking pipeline, and one product driving revenue and growth. All IMO, H

To: Biomaven who wrote (1409)	8/8/2000 7:08:27 AM
From: Micawber	Read Replies (1) \| Respond to of 52153

Peter: Looks to me like you left out the perennial wallflower, LGND. Have waited for years for something, anything to happen here. To paraphrase Mark Twain, the news of their profitability has been greatly exaggerated...over and over again. I'm wondering when this "strategy" of getting restricted labels for obscure indications is going to really pay off. Mr. Market continues to be underwhelmed here.

To: Biomaven who wrote (1409)	8/9/2000 5:30:14 AM
From: nigel bates	Respond to of 52153

How about Cambridge Antibody (CAT.L) - NASDAQ listing coming up soon & sitting at a wholly unjustified discount to ABGX & MEDX ? nig & I'll second Mike on Genset.

To: Biomaven who wrote (1409)	8/9/2000 7:40:57 AM
From: tom pope	Respond to of 52153

>>Let's shift gears and talk about stocks that haven't participated in the rally<< Peter, this doesn't really qualify since I think you were talking longer term than the past 7 days when speaking of a rally, but NBIX has stayed flat while the BTK.X has run from 591 to 669 since 7/31. The divergence is almost certainly to be explained by the disappointing earnings report, but the chart looks like a classic case of congestion, and I'm keeping it on my screen. The longer term up-trend is still intact. I have no position at this time

To: Biomaven who wrote (1409)	8/9/2000 10:24:34 AM
From: aknahow	Read Replies (1) \| Respond to of 52153

Debated a long time about even bothering but for the record XOMA still qualifies as a fallen angel. Experienced, qualified posters on S.I. do not think much of this company. However DNA, BAX and AGN do. Likewise the fact that over 20 companies that have licensed its' cell expression technology say XOMA is doing something right. Anyone with an interest in understanding the depth of Baxter's commitment to Neuprex should read the XOMA 8 K and amendments to the 8 K which deal with the agreement. Between now and December it is very likely Baxter will take a new indication into clinic. Depending on the size of the indication the markets may learn more about the size of potential milestones for other than small indications. In addition Baxter is followed by many analyst. None have so far mentioned XOMA in their reports. If Baxter actually does take Neuprex into clinic it will increase the potential for mention of XOMA by the Baxter analyst. Worldwide research on BPI & LBP continues. Peptides are receiving more coverage and XOMA has said they are close to doing a deal for Mycoprex. (They have said this for a long time). <g> Lilly filed a foreign patent application for a combination of recombinant Protein C with BPI. (No actual use of such a combination was carried out by Lilly, the application was a prophetic patent) The negative case for XOMA is well known. No product on the market. Supposed string of FDA failures, (not exactly correct, but not worth arguing about). Market performance has been erratic over many many years. For those that bother to read the 8 Ks, the Baxter agreement and the "supply" agreement are educational even given, the over 80 facts that remain confidential. The title of Article 7 is not even named but provides for right of first refusal for a product or products in the "Field" covered by the agreement should another company try to license them, etc. This alone could provide some excitement. Conference call on Monday, but no expectations for any positive surprise. However since BAX covers 100% of Neuprex expense, this quarter will be the first to reflect both 3 months of full coverage plus a full 3 months of allocation of part of over $10 million, remain in milestone payments already received. The first quarter was allocated $2 million. I am long XOMA.